Furthermore, when we repeated the meta-analysis excluding ELIXA, the trial done with a short-acting GLP-1 receptor agonist in patients with acute coronary syndrome, the outcome of worsening of kidney function, based predominantly on change in eGFR, was also improved. Sattar and colleagues analyzed data from eight randomized, placebo-controlled trials with 60,080 participants testing injectable or oral GLP-1 receptor agonists in adults with type 2 diabetes, including the recently presented AMPLITUDE-O
Im going to go with ME/CFS here just for consistency
Yes, many patients experience a reduction in visceral and abdominal fat
Asandra about all other medications you are taking and any medical conditions you have
Use a dosage of 1 mcg/kg to 10 mcg/kg body weight for subcutaneous or intramuscular injection
Patients often eat much less